| 0.9798 0.045 (4.79%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.28 |
1-year : | 1.5 |
| Resists | First : | 1.1 |
Second : | 1.28 |
| Pivot price | 0.99  |
|||
| Supports | First : | 0.9 |
Second : | 0.78 |
| MAs | MA(5) : | 0.93 |
MA(20) : | 1 |
| MA(100) : | 1 |
MA(250) : | 1.33 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 23 |
D(3) : | 16.7 |
| RSI | RSI(14): 52.5 |
|||
| 52-week | High : | 3.3 | Low : | 0.7 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RDHL ] has closed above bottom band by 42.3%. Bollinger Bands are 38.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1 - 1.01 | 1.01 - 1.01 |
| Low: | 0.9 - 0.9 | 0.9 - 0.91 |
| Close: | 0.97 - 0.98 | 0.98 - 0.99 |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Thu, 07 May 2026
RedHill Biopharma (NASDAQ: RDHL) ups ATM capacity by $1.59M - Stock Titan
Tue, 05 May 2026
[EFFECT] RedHill Biopharma Ltd. SEC Filing - Stock Titan
Thu, 30 Apr 2026
RedHill Biopharma (RDHL) touts RHB-204 progress and Phase 3-backed Crohn’s strategy - Stock Titan
Mon, 27 Apr 2026
RedHill Biopharma (Nasdaq: RDHL) details 2025 results, Talicia JV and pipeline - Stock Titan
Fri, 17 Apr 2026
RDHL: Talicia leads H. pylori therapy, supported by strong financials and a diversified late-stage pipeline - TradingView
Wed, 25 Feb 2026
Joint U.S. Commercialization of RedHill's Talicia® Commences - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.991e+010 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 20 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.79e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -150 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 765.3 % |
| Return on Equity (ttm) | -22.8 % |
| Qtrly Rev. Growth | 286000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 56746 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 5.87 |
| Dividend | 0 |
| Forward Dividend | 19070 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|